Evidence map›Paper›PMID 26448939›Full record

ArticleBioMed research international2015

BRAF Testing in Multifocal Papillary Thyroid Carcinoma.

Hillary Z Kimbrell, Andrew B Sholl, Swarnamala Ratnayaka, Shanker Japa, Michelle Lacey, Gandahari Carpio, Parisha Bhatia, Emad Kandil

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hillary Z KimbrellDepartment of Pathology and Laboratory Medicine, Tulane University, 1430 Tulane Avenue SL-79, New Orleans, LA 70112, USA.
Andrew B ShollDepartment of Pathology and Laboratory Medicine, Tulane University, 1430 Tulane Avenue SL-79, New Orleans, LA 70112, USA.
Swarnamala RatnayakaDepartment of Pathology and Laboratory Medicine, Tulane University, 1430 Tulane Avenue SL-79, New Orleans, LA 70112, USA.
Shanker JapaDepartment of Pathology and Laboratory Medicine, Tulane University, 1430 Tulane Avenue SL-79, New Orleans, LA 70112, USA.
Michelle LaceyDepartment of Mathematics, Tulane University, 6823 St. Charles Avenue, New Orleans, LA 70118, USA.
Gandahari CarpioDepartment of Medicine, Tulane University, 1430 Tulane Avenue SL-12, New Orleans, LA 70112, USA.
Parisha BhatiaDepartment of Surgery, Tulane University, 1430 Tulane Avenue SL-22, New Orleans, LA 70112, USA.
Emad KandilDepartment of Surgery, Tulane University, 1430 Tulane Avenue SL-22, New Orleans, LA 70112, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBRAF V600E mutation is associated with poor prognosis in patients with papillary thyroid carcinoma (PTC). PTC is often multifocal, and there are no guidelines on how many tumors to test for BRAF mutation in multifocal PTC.

methodsFifty-seven separate formalin-fixed and paraffin-embedded PTCs from twenty-seven patients were manually macrodissected and tested for BRAF mutation using a commercial allele-specific real-time polymerase chain reaction-based assay (Entrogen, Woodland Hills, CA). Data related to histologic characteristics, patient demographics, and clinical outcomes were collected.

resultsAll mutations detected were BRAF V600E. Seventeen patients (63%) had concordant mutation status in the largest and second-largest tumors (i.e., both were positive or both were negative). The remaining ten patients (37%) had discordant mutation status. Six of the patients with discordant tumors (22% overall) had a BRAF-negative largest tumor and a BRAF-positive second-largest tumor. No histologic feature was found to help predict which cases would be discordant.

conclusionsPatients with multifocal PTC whose largest tumor is BRAF-negative can have smaller tumors that are BRAF-positive. Therefore, molecular testing of more than just the dominant tumor should be considered. Future studies are warranted to establish whether finding a BRAF mutation in a smaller tumor has clinical significance.

Indexed as

AdultAgedBiomarkers, TumorCarcinomaCarcinoma, PapillaryFemaleGenetic Predisposition to DiseaseHumansIncidenceLouisianaMaleMiddle AgedMutationPolymorphism, Single NucleotideProto-Oncogene Proteins B-rafReproducibility of ResultsBiomarkers, TumorBRAF protein, humanProto-Oncogene Proteins B-raf

Identifiers

PMID26448939
PMCPMC4584030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.